-
Views
-
Cite
Cite
Edina H. Moylett, Susan E. Pacheco, Barbara A. Brown-Elliott, Tracy R. Perry, E. Stephen Buescher, Mary C. Birmingham, Jerome J. Schentag, Joseph F. Gimbel, Aaron Apodaca, Margot A. Schwartz, Robert M. Rakita, Richard J. Wallace, Clinical Experience with Linezolid for the Treatment of Nocardia Infection, Clinical Infectious Diseases, Volume 36, Issue 3, 1 February 2003, Pages 313–318, https://doi.org/10.1086/345907
- Share Icon Share
Abstract
Linezolid is an oxazolidinone that has activity against most gram-positive bacteria, including in vitro activity against all Nocardia species and strains. We describe 6 clinical cases of nocardiosis that were successfully treated with linezolid. Two patients had underlying X-linked chronic granulomatous disease, and 2 patients were receiving chronic corticosteroid therapy. Four of 6 patients had disseminated disease, and 2 of these 4 patients had multiple brain abscesses. Four patients primarily received monotherapy; for the fifth patient, linezolid was added to a failing multiple-drug regimen, and, for the sixth patient, it was used as part of combination therapy. All 6 patients were successfully treated, although 1 patient had a presumed relapse of central nervous system infection after premature discontinuation of the drug. Linezolid appears to be an effective alternative for the treatment of nocardiosis.